Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Alpha-arbutin is a synthetic glycoside used primarily in the cosmetic and pharmaceutical industries for its skin lightening effects and treatment of hyperpigmentation. It acts as a safer alternative to hydroquinone. The primary mechanism of action is competitive inhibition of tyrosinase, an enzyme essential for melanin synthesis. By inhibiting tyrosinase activity (without affecting its gene expression), alpha-arbutin reduces the formation of melanin in melanocytes, leading to lighter skin tones and improvement in hyperpigmentation disorders. Alpha-arbutin has been shown to be more potent than arbutin itself as a tyrosinase inhibitor[1][6][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on alpha-arbutin.